In a 60-year-old patient with clinical stage III adenocarcinoma of the lung, treatment with 160 mg of selpercatinib twice daily, in 28-day cycles, led to a rapid decrease in the estimated glomerular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback